Special Program of Assisted Reproduction

AIS Healthcare Leadership Featured at NASP 2023 Annual Meeting and Expo

Retrieved on: 
Monday, September 25, 2023
General Health, Pharmaceutical, Health, Parkland Health & Hospital System, TDD, Doctor of Pharmacy, Pharmacy, CNSC, Ochsner Health System, Baylor Scott & White Health, Pharmacopoeia, MBA, AIS, USP, Pharmacist, NASP, Specialty pharmacy, Guideline, Patient, Category 3, Special Program of Assisted Reproduction, CPPS, National Association, Safety, Medical device, Hospital

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, announced its participation in the National Association of Specialty Pharmacy (NASP) 2023 Annual Meeting and Expo, which took place on September 18th – 21st in Grapevine, Texas.

Key Points: 
  • AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, announced its participation in the National Association of Specialty Pharmacy (NASP) 2023 Annual Meeting and Expo, which took place on September 18th – 21st in Grapevine, Texas.
  • At the NASP 2023 Annual Meeting and Expo, AIS Healthcare sponsored a continuing education symposium through an unrestricted educational grant that focused on the critical topic of USP 797 guideline revisions, a set of standards developed by U.S. Pharmacopeia (USP) governing the safe compounding of sterile preparations in healthcare settings, and its impact on the healthcare industry.
  • AIS Healthcare is honored to have participated in the NASP 2023 Annual Meeting and Expo and is committed to fostering innovation and excellence in pharmaceutical compounding.
  • For more information about the NASP 2023 Annual Meeting and Expo, please visit www.naspmeeting.com .

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Retrieved on: 
Tuesday, September 12, 2023
Research Excellence Framework, Yale Cancer Center, Yale University, S15, Myelocyte, Yale School of Medicine, Special Program of Assisted Reproduction, Cancer research, Clinical trial, RECIST, Cancer, Trae tha Truth, SITC, Pneumonitis, DRS, Oncology, Research, Lung cancer, Rash, Psoriasis, HIV disease progression rates, Patient, Immunoglobulin G, Translational research, Pericarditis, Mab, Ensign, Transverse myelitis, PD-1, Pembrolizumab, United Technologies, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Medicine, Dermatology, NSCLC, Pharmacology

BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2 clinical data by collaborators at the Yale Cancer Center demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.

Key Points: 
  • In an earlier monotherapy study from NextCure, NC318 demonstrated single agent activity in a Phase 1/2 dose escalation trial (NCT03665285) for patients with advanced solid tumors (Tolcher et al, SITC 2019).
  • The ongoing NCT04699123 study is a randomized trial designed to assess the safety and efficacy of NC318 alone or in combination with pembrolizumab.
  • The combination portion of the study is assessing efficacy in NSCLC subjects who have experienced disease progression on, or after, PD-1 axis inhibitor therapy.
  • NC318 infusion reactions were seen in seven patients (three Grade 3, four Grade 2), six receiving the combination and one NC318 alone.

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

Retrieved on: 
Tuesday, September 12, 2023
Linda, SAB, Special Program of Assisted Reproduction, Biotechnology, Northwest Biotherapeutics, OTCQB, United States Air Force Scientific Advisory Board, MBA, Research, Doctor of Philosophy, Brain, Glioblastoma, Professor, Journal, National academy, Buenos Aires National Academy of Medicine, MD, Journal of Neuro-Oncology, Biology, Knowledge, Principal, UCLA, Centers of Biomedical Research Excellence, Medical imaging, Medical device

BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).

Key Points: 
  • BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
  • Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma.
  • She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program.
  • Linda Powers, NWBio CEO, commented:  "We are delighted to have Dr. Liau join our existing distinguished SAB.

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

Retrieved on: 
Tuesday, September 12, 2023
Linda, SAB, Special Program of Assisted Reproduction, Biotechnology, Northwest Biotherapeutics, OTCQB, United States Air Force Scientific Advisory Board, MBA, Research, Doctor of Philosophy, Brain, Glioblastoma, Professor, Journal, National academy, Buenos Aires National Academy of Medicine, MD, Journal of Neuro-Oncology, Biology, Knowledge, Principal, UCLA, Centers of Biomedical Research Excellence, Medical imaging, Medical device

BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).

Key Points: 
  • BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
  • Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma.
  • She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program.
  • Linda Powers, NWBio CEO, commented:  "We are delighted to have Dr. Liau join our existing distinguished SAB.

Global Infertility Treatment Devices and Equipment Market Report 2023: Continuous Rise in Infertility Rates Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023
General Health, Health, Other Health, Prevalence, Semen, ART, Infertility, Fertility clinic, USD, IVF, CDC, Special Program of Assisted Reproduction, Korea Disease Control and Prevention Agency, Assisted reproductive technology, Growth, Patient, Insemination, Birth control

The "Infertility Treatment Devices And Equipment Market Size, Share & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infertility Treatment Devices And Equipment Market Size, Share & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global infertility treatment devices and equipment market size is expected to reach USD 555.2 million by 2030.
  • High adoption of Assisted Reproductive Technology (ART) is a significant driver in the market for infertility treatment devices & equipment.
  • The number of medical centers providing infertility treatment has increased over the past few years due to an increase in the prevalence of infertility cases around the world.

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Wednesday, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Hamilton Thorne to Present at Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Wednesday, July 27, 2022
Reproductive technology, TSX, GLOBE, TSX Venture Exchange, HTL, Fertility clinic, CEO, Planer, Research, Software, Assisted reproductive technology, Conference, EDT, ART, Special Program of Assisted Reproduction

To schedule a meeting with management, please contact your conference representative or email [email protected] .

Key Points: 
  • To schedule a meeting with management, please contact your conference representative or email [email protected] .
  • Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets.
  • Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide.
  • Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Orion Space Solutions supports CAPSTONE Program for NASA Moon Missions

Retrieved on: 
Monday, July 18, 2022
CAPSTONE (spacecraft), OSS, Special Program of Assisted Reproduction, Solution, Communication, Knowledge, Moon, Engineering, Science, Artemis, Gateway, Spacecraft, Technology, Chip-scale atomic clock, NASA, GPS, Human, Physics, Risk, CSAC, Senior, CubeSat, Atomic clock, Astronaut, Communications satellite

LOUISVILLE, Colo., July 18, 2022 /PRNewswire/ -- NASA launched its Cislunar Autonomous Positioning System Technology Operations and Navigation Experiment (CAPSTONE) on June 28, as a part of the Artemis program, to study a specific orbit for the future Gateway lunar station. Led by Advanced Space, this mission is test driving orbital analysis that will enable NASA's future exploration efforts. Orion Space Solutions (OSS) provides a critical satellite component that will support mission success.

Key Points: 
  • Orion Space Solutions (OSS) provides a critical satellite component that will support mission success.
  • "OSS engineers and scientists develop space solutions that work," says Mr. Erik Stromberg, OSS Senior Director of Special Programs.
  • CAPSTONE is set to arrive at the moon in November, when it will begin its 6-month long primary mission.
  • About Orion Space Solutions: Orion Space Solutions (OSS) was born from the vision to apply fundamental space physics knowledge to real-world problems.

Global Infertility Treatment Market to Reach $2.1 Billion by 2026

Retrieved on: 
Tuesday, March 22, 2022
CAGR, Reproductive technology, PCOS, Infertility, Forecasting, Research, Developing country, IVF, Incidence, Thermo Fisher Scientific, Equipment, The Cooper Companies, Obesity, Players, Marketing, Diagnosis, Artificial insemination, Consumables, Female, Merck Group, Growth, Internet, Intelligence, Digital Media Consumers' Rights Act, Awareness, SAN, Anovulation, Special Program of Assisted Reproduction, GIA, COVID-19, ART, Endometriosis, Hospital, Pharmaceutical industry, Birth control, Pet, Media

SAN FRANCISCO, March 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infertility Treatment - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infertility Treatment - Global Market Trajectory & Analytics" .
  • Awareness about different infertility treatment procedures, increasing female infertility rate, and rising number of fertility centers will contribute the growth of female infertility treatment.
  • Amid the COVID-19 crisis, the global market for Infertility Treatment estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$2.1 Billion by 2026, growing at a CAGR of 6.7% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Join Coastline College This #GivingTuesday and Help Change the Lives of Our Students

Retrieved on: 
Tuesday, November 23, 2021
Foundation, Housing, Service, Human, Student, VRC, Disability, Coastline Community College, Special Program of Assisted Reproduction, Twitter, Topical steroid withdrawal, Organization, Instagram, Friends, Giving Tuesday, Aspen Institute, Western Association of Schools and Colleges, Tutoring, Medicine

On Tuesday, November 30th, Coastline College is participating in #GivingTuesday, and would like to invite our community members, alumni, and employees to contribute and support students in need.

Key Points: 
  • On Tuesday, November 30th, Coastline College is participating in #GivingTuesday, and would like to invite our community members, alumni, and employees to contribute and support students in need.
  • Coastline students continue to be affected by the economic impact of COVID-19.Vulnerable students need assistance, including first-generation college students, military veterans, nontraditional students, and the entire diverse group of students who are a part of our campus community.
  • https://www.coastline.edu/events/giving-tuesday-2021.php
    Coastline College is committed to our student success and provides an array of support programs and services to meet the diverse needs of our students.
  • The funds received through our Giving Tuesday Campaign will allow our Coastline Foundation to help more students to complete their educational goals."